US bets $1.2B on Merck's last hope for a COVID-19 drug

The U.S. government has agreed to pay Merck & Co. $1.2 billion for roughly 1.7 million courses of an experimental COVID-19 drug should the treatment, currently in late-stage testing, win emergency authorization.